(Q35840402)

10 August 2017

title

Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies (English)

1 reference

10 August 2017

1 reference

Denise Uyar

1

1 reference

10 August 2017

Barbara Kulp

2

1 reference

10 August 2017

Gertrude Peterson

3

1 reference

10 August 2017

Kristine Zanotti

4

1 reference

10 August 2017

Maurie Markman

5

1 reference

10 August 2017

Jerome Belinson

6

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

94

1 reference

10 August 2017

issue

1

1 reference

10 August 2017

page(s)

147-151

1 reference

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Risk factors for doxorubicin-induced congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

A clinicopathologic analysis of adriamycin cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Adriamycin cardiomyopathy--risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Pegylated liposomal doxorubicin: tolerability and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Review of tests for monitoring doxorubicin-induced cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Multiple gated cardiac blood pool imaging for left ventricular ejection fraction: Validation of the technique and assessment of variability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.024

10.1016/J.YGYNO.2004.03.024

7 January 2021

Identifiers

DOI

1 reference

10 August 2017

1 reference